Affluent Medical reports that Jean-François Le Bigot who currently serves as CEO of Oncovita and Chairman of Ginko Invest has been appointed to the board. He was previously Chairman of Citoxlab Group (formerly CIT) that he joined in 1987. Over a period of more than 30 years, he developed and expanded Citoxlab which became a leading International CRO with more than 1500 employees. Under his leadership, Citoxlab acquired many CROs in North America and Europe. He successfully sold Citoxlab in 2019 to Charles River. He previously held executive positions at Sandoz Laboratories. Jean-François holds a Ph.D. in Biomedical pharmacology.
In addition, Benoit Adelus with more than 30 years of experience in the healthcare, MedTech, in vitro diagnostics, vaccines and animal health sectors where he led a number of successful companies that he developed significantly through innovation, international expansion and acquisitions in the US and China, in particular, has been appointed. He has strong international experience having held different positions, from VP Commercial Operations, R&D to CEO in the US, and Latin America. Mr. Adelus led the IPO of bioMerieux on the Paris stock exchange in 2004 as CEO. He has extensive experience in LBOs, having led a total of four highly successful transactions and served as Chairman or Board Member of various Healthtech companies.
Michel Finance, CEO of Affluent Medical, was also appointed board member and elected Chairman of the Board.